CRISPR Therapeutics AG 2025年季度报告

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF (Address of principal executive offices)+41 (0)41561 32 77 or emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Non-accelerated filer☐Smaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ “our,” except where the context requires otherwise, refer to CRISPR Therapeutics AG and its consolidated subsidiaries; “ourboard of directors” refers to the board of directors of CRISPR Therapeutics AG; and we generally refer to CASGEVY®(exagamglogene autotemcel [exa-cel]), as “CASGEVY”. “CRISPR Therapeutics®” standard character mark and design logo, “CRISPRXTM“CTX131TM,” “CTX211TM,” “CTX213TM,” “CTX310TM,” “CTX320TM,” “CTX330TM trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY®trademarks of Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals Incorporated is the manufacturer and exclusive This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve substantial risks and uncertainties.All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q are forward-looking looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:•our strategic plans to develop and, if approved, subsequently commercialize any product candidates we may develop,including plans and expectations for the commercialization of, and anticipated benefits of, CASGEVY, including plans •our ability to advance product candidates into, and successfully complete, clinical trials; our estimates regarding the addressable patient population and potential market opportunity for our current and futureproduct candidates;•the rate and degree of market acceptance of our product candidates and the success of competing therapies that are orbecome available; •our internal manufacturing capabilities and operation of our cell therapy manufacturing facility; •our intellectual property coverage and positions, including those of our licensors and third parties as well as the statusand potential outcome of proceedings involving any such intellectual property;•the expected benefits of our collaborations; •our strategy, goals, and anticipated financial performance;•our anticipated expenses, ability to obtain funding for our operations andthe sufficiency of our cash resources; •the therapeutic value, development, and commercial potential of gene editing technologies and therapies, includingCRISPR/Cas9, as well as other technologies we develop; and •the volatility of capital markets and unfavorable macroeconomic conditions resulting from factors including risinginflation, international tariffs, interest rate and currency rate fluctuations, economic sanctions and economic slowdownor recession, banking instability, monetary policy changes, geopolitical tensions or the outbreak of hostilities or war. Report on Form 10-Q completely and with the understanding that our actual future results, performance or achievements may bematerially different from what we expect. Except as required by law, we undertake no obligation to update any forward-lookingstatements to reflect events or circumstances after the date of such statements. PART I: FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (unaudited)Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2025 Condensed Consolidated Balance Sheets(unaudited, in thousands, except share and per share data) 1,620,101—Prepaid expenses and other current assets12,326 Reconciliation of net loss to net cash used in operating activities: Accounts payable and accrued expensesDeferred revenue Operating lease assets and liabilities (10,541)Net cash (used in) provided by operating activities(53,947) Purchase of property, plant and equipment(206)Investment in equity securities(5,000)Purchases of marketable securities(200,730)Maturities of marketable securities186,181Net cash used in investing activities(19,755)Financing activities: Net cash provided by financing activities10,588Effect of exchange rate changes on cash41(Decrease) increase in cash(63,073)Cash, cash equivalents and restricted cash, beginning of period309,776 Supplemental disclosure of non-cash investing and financing activitiesEquity issuance costs in accounts payable, accrued expenses, and other long-term $3,219$As of March 31,Reconciliation to amounts within the condensed consolidated balance sheets20252024